Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia

Ying Zhang,Yan Wang,Mieke L. Van Driel,Treasure M. McGuire,Tao Zhang,Yuzhu Dong,Yang Liu,Leichao Liu,Ruifang Hao,Lu Cao,Jianfeng Xing,Yalin Dong

DOI: https://doi.org/10.1186/s13756-019-0518-2

IF: 6.454

2019-05-06

Antimicrobial Resistance and Infection Control

Abstract:BackgroundInfections due to methicillin-resistant Staphylococcus aureus (MRSA) cause serious health risks and significant economic burdens and the preferred drugs are still controversial.

infectious diseases,public, environmental & occupational health,microbiology

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on the following aspects:

1. **Comparison of efficacy**: Through network meta - analysis (NMA), compare the efficacy of different antibiotics in treating complicated skin and soft structure infections (cSSSI) and hospital - acquired or ventilator - associated pneumonia (HAP/VAP) caused by methicillin - resistant Staphylococcus aureus (MRSA).

2. **Safety assessment**: Besides efficacy, this study also evaluated the safety of these antibiotics, especially the incidence of adverse events caused during the treatment process.

3. **Cost - effectiveness analysis**: By establishing a decision - tree model, evaluate the cost - effectiveness of these antibiotics from the patient's perspective to determine which drugs are not only effective but also economical in treating MRSA infections.

Specifically, the main purposes of the study are:
- To compare the clinical cure rates and safety of 16 antibiotics such as linezolid, tedizolid, and vancomycin in treating cSSSI and HAP/VAP.
- To evaluate the cost - effectiveness of these antibiotics in treating MRSA infections, especially the incremental cost - effectiveness ratios (ICERs) compared with vancomycin.

The research results show that in cSSSI, the clinical cure rate of linezolid is significantly higher than that of vancomycin (OR 1.55, 95% CI 1.19 – 2.02), while the efficacy of tedizolid is similar to that of vancomycin (OR 1.39, CI 0.70 – 2.76). In terms of safety, no significant differences were found in the total adverse events between any two intervention measures. From the perspective of cost - effectiveness, linezolid and tedizolid have higher cost - effectiveness than vancomycin, with ICERs of US$2,833 and US$5,523 respectively.

For HAP/VAP, there are no significant differences between linezolid and vancomycin in terms of clinical cure rate and safety, but linezolid has higher cost - effectiveness, with an ICER of US$2,185.

In conclusion, this study provides new insights into the treatment of MRSA infections, especially in the comprehensive evaluation of efficacy, safety, and cost - effectiveness, which is helpful for guiding clinicians to select appropriate treatment regimens.